Speaker illustration

Mr Thomas Michaeli

Mannheim (Germany)

Medical doctor at the University Medical Centre Mannheim at Heidelberg University and clinican scientist at the DKFZ-Hector Institute for Personalized Oncology at the German Cancer Research Center (DKFZ). Research interests include cardiology, oncology, and health policy.

Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Event: ESC Congress 2022

Topic: Health Economics

Session: Costs and cost-effectiveness

Thumbnail

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Event: ESC Congress 2022

Topic: Drug therapy

Session: Lipids - Drug therapy 1

Thumbnail

This platform is supported by

logo Novo Nordisk